FDA has granted IDE approval for the STROKE-REWIRE pivotal trial evaluating NeuWire Medical's neurostimulation device for chronic ischemic stroke recovery.
Poll|Articles|May 7, 2025
Physician Survey: Assessing Cognitive Decline in Primary Care
Author(s)Patient Care Editorial Staff
Primary care clinicians are on the frontline of detecting early cognitive decline. Help us understand your challenges by taking this short survey.
Advertisement
Primary care clinicians are most often the first health care professionals to detect changes that signal potential cognitive decline. Patient Care would like to better understand your current approaches to clinical assessment of early cognitive impairment and any challenges to your screening efforts.
Results of this short survey (~2 minutes to complete) will help us focus our editorial content to your needs and interests. Thank you for participating.
Take the Physician Survey: Assessing Cognitive Decline in Primary Care
Advertisement
Related to this article
Catch up on the 9 FDA drug approvals most relevant to primary care, including new options for HIV-1 infection, narcolepsy, diabetes, pain management, and more.
Stroke incidence in adults aged 20–54 nearly doubled from 1993–1994 to 2020, driven largely by ischemic stroke, while 30-day fatality declined, according to new research.
A team-based blood pressure intervention delivered through primary care reduced dementia risk by 15% over 7 years.
Physical activity was associated with up to 22% lower mortality and 19% lower stroke risk in adults with and without atrial fibrillation in a large Norwegian cohort study.
FDA approves olanzapine, a once-monthly subcutaneous injection for adults with schizophrenia, boosting symptom control while reducing monitoring needs and highlighting weight risks.
The CardioGuide HF app from Abbott will show patients their pulmonary artery pressure trends and deliver medication instructions set by their care teams.
EASD 2026: Oral semaglutide users lost 4.1% of body weight 3 months after switching from injections in an observational study without a comparator group.
Advertisement
Advertisement
Trending on Patient Care Online
1
FDA Approves Once-Monthly Olanzapine Injection for Adults With Schizophrenia
2
9 Drugs Approved for Primary Care: Q3 2026
3
Abbott Gains FDA Approval for CardioMEMS Update Letting Heart Failure Patients View Pressure Readings on Their Phones
4
Multicomponent Strategies to Ease Vaccination Pain and Fear Across Ages
5